Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients aged ≥ 18 to ≤ 85 years.~2. Must receive SoC treatment for ITP that has been stable in dose and frequency for at least 4 weeks prior to Screening. SoC may include oral corticosteroids and/or permitted oral immunosuppressants and/or TPO-R agonist.~3. Confirmed diagnosis of ITP with blood platelet counts \< 30 × 109/L and who have not experienced major bleeding in the last 4 weeks prior to Screening.~Exclusion Criteria:~1. Use of anticoagulants, or any drug with antiplatelet effect within 3 weeks prior to Screening.~2. Patients who have received any blood support or transfusion within 4 weeks prior to Screening.~3. Use of Intravenous immunoglobulin G (IVIg) or anti-D immunoglobulin treatment within 4 weeks prior to screening.~4. Use of recombinant thrombopoietin at any time.~5. Use of rituximab within 6 months prior to Screening. Use of any anti-CD20 other than rituximab at any time is not permitted.~6. Use of immunosuppressants is not permitted within 4 weeks prior to Screening, with the exception of the following oral immunosuppressants: azathioprine, danazol, mycophenolate mofetil, mycophenolate sodium which must have been stable for at least 4 weeks prior to Screening.~7. Use of any other biological therapy or investigational drug than those previously indicated within 3 months or 5 half-lives of the drug (whichever is longer) prior to Screening.~8. Received vaccinations within 4 weeks prior to Screening or planned during the study.~9. At Screening, have clinically significant laboratory abnormalities~10. History of any thrombotic or embolic event within 12 months prior to Screening.~11. Known auto-immune disease other than ITP.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ARGX-113 Dose A + SoC (Type: EXPERIMENTAL): Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
- ARGX-113 Dose B +SoC (Type: EXPERIMENTAL): Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
- Placebo + SoC (Type: PLACEBO_COMPARATOR): Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).